Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma

Table 2 Comparison of tumors from different patient groups based on frequencies of hypermethylation at miRNA loci

	Proportion of tumors with hypermethylation ^a
Tumor category	572	129-2	663	375-I	345	132	34a
MSI vs. MSS
Sporadic Finnish MSI-CRC (n = 40) vs. sporadic Finnish MSS-CRC (n = 47)	13/40 vs. 13/47	37/40 vs. 34/47	28/40 vs. 28/47	0/40 vs. 1/47	24/40 vs. 13/47*	23/40 vs. 1/47***	23/40 vs. 20/47
Sporadic Australian MSI-CRC (n = 38) vs. sporadic Australian MSS-CRC (n = 52)	9/38 vs. 9/52	28/38 vs. 42/52	30/38 vs. 44/52	10/38 vs. 14/52	13/38 vs. 5/52*	15/38 vs. 6/52*	10/38 vs. 15/52
Sporadic vs. hereditary
Sporadic Finnish MSI-CRC (n = 40) vs. Finnish Lynch-CRC (n = 28)	13/40 vs. 12/28	37/40 vs. 23/28	28/40 vs. 18/28	0/40 vs. 8/28**	24/40 vs. 12/28	23/40 vs. 2/28***	23/40 vs. 13/28
Colorectal vs. endometrial
Finnish Lynch-CRC (n = 28) vs. Finnish Lynch-EC (n = 36)	12/28 vs. 16/36	23/28 vs. 16/36*	18/28 vs. 22/36	8/28 vs. 5/36	12/28 vs. 3/36*	2/28 vs. 11/36	13/28 vs. 20/36
Finnish vs. Australian
Sporadic Finnish MSI-CRC (n = 40) vs. sporadic Australian MSI-CRC (n = 52)	13/40 vs. 9/38	37/40 vs. 28/38	28/40 vs. 30/38	0/40 vs. 10/38**	24/40 vs. 13/38	23/40 vs. 15/38	23/40 vs. 10/38*
Sporadic Finnish MSS-CRC (n = 47) vs. sporadic Australian MSS-CRC (n = 52)	13/47 vs. 9/52	34/47 vs. 42/52	28/47 vs. 44/52*	1/47 vs. 14/52**	13/47 vs. 5/52	1/47 vs. 6/52	20/47 vs. 15/52

^aUsing cutoffs determined by methylation in the respective normal tissues (Additional file 8: Table S5). P values determined by Fisher’s exact test and adjusted for multiple testing are shown after each comparison, (* P < 0.05; ** P < 0.01; *** P < 0.001). All tumors were informative for all markers.

ISSN: 1868-7083